Super Fast Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Super Fast Pharma
British racing car company and GlaxoSmithKline team up on a winning formula for innovation.


Pharmaceutical Technology
pp. 14


Rich Whitworth
Partnerships and strategic agreements are common in the pharma industry. But one particular announcement last month gave me cause to raise my eyebrows and smile.

I like fast cars and so too, it would seem, does GlaxoSmithKline's CEO Andrew Witty because the company is embarking on a long-term strategic partnership with the McLaren group, which is best known for its Formula 1 racing cars. The phrase "best of British" springs to mind and both companies seem extremely proud of the partnership.

The aim for GSK? Applying McLaren's engineering and technical expertise to production lines to reduce breakdowns and improve costs, amongst other things.

A state-of-the-art facility planned for 2013 called The McLaren GSK Centre for Applied Performance will allow scientists, engineers, and technologists from both camps to share ideas and collaborate on innovative, dynamic, and exciting joint working projects.

The R&D organization will examine whether real-time monitoring technologies can be applied to human studies. Meanwhile, the GSK Consumer Healthcare business will work with McLaren's "Mission Control" unit to enable faster responses to competitor activity and customer needs.

Some might say that it smacks of a marketing stunt, but which pharma company wouldn't want to be associated with such a fast-paced, exciting, technologically advanced, continually improving world?

What next? Sanofi and Red Bull Racing? The race to the checkered flag is on!

Rich Whitworth is an editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here